## Clinical Context This patient presents with the classic pentad of kala-azar: fever, weight loss, hepatosplenomegaly, anemia, and thrombocytopenia. Positive serology combined with clinical features and pancytopenia is sufficient to diagnose visceral leishmaniasis in an endemic region. ## Treatment Algorithm for Kala-azar **Key Point:** Liposomal amphotericin B is the first-line treatment for kala-azar in India due to superior efficacy, lower toxicity, and reduced risk of treatment failure compared to older agents. **High-Yield:** The WHO and Indian guidelines (2019) recommend liposomal amphotericin B as the gold standard for visceral leishmaniasis, especially in: - Immunocompromised patients - Patients with severe organ dysfunction (as evidenced by pancytopenia here) - Areas with antimonial resistance - Pregnant women ## Dosing and Regimen | Agent | Dose | Duration | Notes | |-------|------|----------|-------| | **Liposomal Amphotericin B** | 3 mg/kg IV daily | 10 doses over 15–21 days | First-line; 95% cure rate | | Sodium Stibogluconate | 20 mg/kg/day IM | 30 days | Older agent; resistance in Bihar/UP | | Miltefosine | 2.5 mg/kg/day PO | 28 days | Oral option; slower response; teratogenic | | Paromomycin | 15 mg/kg/day IM | 21 days | Alternative; less effective alone | **Clinical Pearl:** This patient's severe pancytopenia and hepatosplenomegaly indicate advanced disease. Liposomal amphotericin B penetrates the reticuloendothelial system better and has fewer nephrotoxic effects, making it ideal when bone marrow is already compromised. **Tip:** Serology positivity (rK39 ELISA or DAT) in an endemic region with clinical features is diagnostic—bone marrow aspiration is NOT required before treatment initiation. Delaying therapy risks mortality. [cite:Park 26e Ch 32]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.